ストックスクリーナーアプリを入手
0.7585
2.71%
0.02
前日終値:
$0.7385
開ける：
$0.7428
24時間の取引高:
683.59K
Relative Volume:
0.81
時価総額：
$97.98M
収益：
-
当期純損益:
$-26.91M
株価収益率:
-3.4477
EPS:
-0.22
ネットキャッシュフロー:
$-19.57M
1週間 パフォーマンス:
-2.73%
1か月 パフォーマンス:
-10.56%
6か月 パフォーマンス:
-11.50%
1年 パフォーマンス:
-35.17%
1日の値動き範囲:
$0.734
$0.7741
1週間の範囲:
$0.6848
$0.7997
52週間の値動き範囲:
$0.5526
$1.2982
Atossa Therapeutics Inc Stock (ATOS) Company Profile
名前
Atossa Therapeutics Inc
セクター
電話
206.588.0256
住所
10202 5TH AVENUE NE, SEATTLE, WA
ATOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.7585 | 95.39M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-01-26 | 開始されました | Maxim Group | Buy |
Atossa Therapeutics Inc (ATOS) 最新ニュース
Will Atossa Therapeutics Inc. stock outperform tech sector in 2025July 2025 Recap & Safe Capital Investment Plans - Newser
Is Atossa Therapeutics Inc. (YAG2) stock a buy before new product rolloutQuarterly Portfolio Report & Fast Momentum Entry Tips - Newser
Atossa Completes FDA Meeting on Regulatory Strategies - TipRanks
Atossa Therapeutics Completes FDA Meeting on (Z)-Endoxifen Strategy - TradingView
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - PR Newswire
Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of "Hold" by Analysts - MarketBeat
Is Atossa Therapeutics Inc. (YAG2) stock considered safe havenJuly 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Is Atossa Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Big Picture & Step-by-Step Swing Trade Plans - Newser
Is Atossa Therapeutics Inc. (YAG2) stock good for long term investingWeekly Investment Summary & Low Risk Entry Point Guides - Newser
Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - Setenews
Will Atossa Therapeutics Inc. stock beat EPS estimates2025 Key Highlights & High Return Stock Watch Alerts - Newser
How Atossa Therapeutics Inc. (YAG2) stock performs in easing cyclesWeekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser
S P Trends: How buybacks impact ARMOUR Residential REIT Inc stock valuePrice Action & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ
Atossa Therapeutics (ATOS) Advances Glioblastoma Research with A - GuruFocus
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma (2025-12-02) - Seeking Alpha
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - Sahm
Can Atossa Therapeutics Inc. (YAG2) stock surprise with quarterly results2025 Momentum Check & Fast Gain Stock Tips - Newser
Published on: 2025-12-02 04:01:13 - Newser
Will Atossa Therapeutics Inc. (YAG2) stock hit Wall Street targetsOptions Play & Precise Trade Entry Recommendations - Newser
Will Atossa Therapeutics Inc. stock outperform international peersJuly 2025 Levels & Fast Moving Market Watchlists - BỘ NỘI VỤ
Is Atossa Therapeutics Inc (ATOS) positioned for future growth? - Setenews
Is Atossa Therapeutics Inc. stock a buy before product launches2025 Major Catalysts & Verified Momentum Watchlists - BỘ NỘI VỤ
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer (PR Newswire) - Aktiellt
Atossa Therapeutics, Inc. (ATOS) 5.16% in After-hours: What’s Driving the Move? - Stocks Telegraph
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer (PR Newswire) - Aktiellt
Why Atossa Therapeutics Inc. (YAG2) stock is listed among top recommendationsRecession Risk & Verified High Yield Trade Plans - newser.com
Is Atossa Therapeutics Inc a good long term investmentTop Performing Stocks & Free Extraordinary Earning Power - earlytimes.in
How buybacks impact Atossa Therapeutics Inc. stock value2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock profit from AI boomWeekly Profit Report & Fast Gaining Stock Reports - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock remain on Wall Street radarWeekly Investment Report & Verified Short-Term Trading Plans - newser.com
How Atossa Therapeutics Inc. stock valuations compare to rivalsPortfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
How rising interest rates impact Atossa Therapeutics Inc. stockMarket Performance Recap & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-11-19 18:15:24 - newser.com
Published on: 2025-11-19 15:47:35 - newser.com
Is a relief rally coming for Atossa Therapeutics Inc. holdersJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock deliver consistent EPS growthLayoff News & Real-Time Volume Analysis Alerts - newser.com
Does Atossa Therapeutics Inc. fit your quant trading modelWeekly Profit Recap & Weekly Watchlist of Top Performers - newser.com
Is Atossa Therapeutics Inc. reversing from oversold territoryJuly 2025 Sentiment & Stock Portfolio Risk Management - newser.com
Published on: 2025-11-19 03:34:37 - newser.com
What insider trading reveals about Atossa Therapeutics Inc. stockPortfolio Value Summary & Accurate Buy Signal Alerts - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price target2025 Short Interest & Real-Time Volume Triggers - newser.com
Atossa Therapeutics Inc (ATOS) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):